GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

AnaptysBio’s trial saw 69% of its rheumatoid arthritis patients treated with rosnilimab achieve low disease activity by week ...

Moleculin Biotech has received approval in Ukraine to begin enrolment in its trial of annamycin with cytarabine for acute ...

Patients who received a single injection of Lumevoq displayed sustained clinical recovery in a rare condition that can lead ...

Rallybio has dosed the first subject in a trial of a potential treament for foetal and neonatal alloimmune thrombocytopaenia (FNAIT).

Being realistic, responsive and transparent is key in engaging unresponsive and underperforming clinical trial sites; that ...

Trump's tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.

The trial will see healthy volunteers infected with dengue to test the impact of AbViro’s monoclonal antibody therapy.

Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

Historical epidemiological analysis has demonstrated an association between urbanisation and growing cancer burden across the ...

Palvella Therapeutics is set to expand Phase III SELVA trial to include subjects aged three to five years old.

Q32 Bio has stopped a Phase II trial of its former lead renal disease candidate as it focuses on its alopecia areata ...